DRAXIMAGE SESTAMIBI DIN 02327732
Status: Marketed
Holder: JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA
Molecule: TETRAKIS [CU(MIBI)4]BF4
Health Canada record
| Active ingredient(s) | TETRAKIS [CU(MIBI)4]BF4 1 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09GA01 TECHNETIUM (99m Tc) SESTAMIBI |
| Original market date | 06-Feb-2009 |
| Current status date | 23-Aug-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jubilant Draximage Inc. dba Jubilant Radiopharma — licence 101869, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TETRAKIS [CU(MIBI)4]BF4
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02328003 | CARDIOLITE | LANTHEUS MI CANADA INC | Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Marketed |
| 02329794 | KIT FOR THE PREPARATION OF TECHNETIUM TC 99M SESTAMIBI INJECTION | CURIUM CANADA INC | Kit; Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Marketed |
| 02327929 | MIRALUMA | LANTHEUS MI CANADA INC | Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Cancelled Pre Market |